ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

NANO Nanobiotix

4.796
0.026 (0.55%)
Last Updated: 12:46:21
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nanobiotix EU:NANO Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.026 0.55% 4.796 4.772 4.798 4.804 4.754 4.804 6,712 12:46:21

Nanobiotix Shares Soar on Licensing Deal With J&J Unit

10/07/2023 11:57am

Dow Jones News


Nanobiotix (EU:NANO)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more Nanobiotix Charts.

By Colin Kellaher

 

U.S.-listed shares of Nanobiotix surged in premarket trading Monday after the clinical-stage biotechnology company said it inked a licensing, co-development and commercialization agreement potentially worth billions of dollars with a unit of drug giant Johnson & Johnson.

Paris-based Nanobiotix said it will grant J&J's Janssen Pharmaceutical unit a worldwide license for the development and commercialization of NBTXR3, a radioenhancer currently being evaluated in several studies across solid tumor indications.

Nanobiotix said it will receive near-term cash and operational support valued up to $60 million, including a $30 million upfront cash licensing fee and up to $30 million in in-kind regulatory and development support for a current Phase 3 study evaluating NBTXR3 for the treatment of patients with locally advanced head and neck cancer.

Nanobiotix said it is eligible for up to $1.8 billion in payments related to potential development, regulatory and sales milestones, along with royalties on product sales.

The company said the agreement also includes a framework for up to $650 million in additional milestone payments for five new indications that Janssen may develop at its discretion, as well as up to $220 million per indication that Nanobiotix may develop in alignment with Janssen.

Nanobiotix's U.S.-listed shares, which closed Friday at $5.18, were recently up nearly 52% to $7.85 in premarket trading. The company's Paris-listed shares were up 53% to EUR7.15.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

July 10, 2023 06:42 ET (10:42 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

1 Year Nanobiotix Chart

1 Year Nanobiotix Chart

1 Month Nanobiotix Chart

1 Month Nanobiotix Chart

Your Recent History

Delayed Upgrade Clock